<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Subst Abuse Treat Prev Policy</journal-id><journal-id journal-id-type="iso-abbrev">Subst Abuse Treat Prev Policy</journal-id><journal-title-group><journal-title>Substance Abuse Treatment, Prevention, and Policy</journal-title></journal-title-group><issn pub-type="epub">1747-597X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">266</article-id><article-id pub-id-type="doi">10.1186/s13011-020-00266-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Farhadian</surname><given-names>Negin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Moradi</surname><given-names>Sajad</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zamanian</surname><given-names>Mohammad Hossein</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Farnia</surname><given-names>Vahid</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rezaeian</surname><given-names>Shahab</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Farhadian</surname><given-names>Maryam</given-names></name><address><email>maryam_farhadian80@yahoo.com</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Shahlaei</surname><given-names>Mohsen</given-names></name><address><email>m.shahlaei@kums.ac.ir</email><email>mohsenshahlaei@yahoo.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.412112.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2012 5829</institution-id><institution>Substance Abuse Prevention Research Center, Health Institute, </institution><institution>Kermanshah University of Medical Sciences, </institution></institution-wrap>Kermanshah, Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.412112.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2012 5829</institution-id><institution>Nano Drug Delivery Research Center, Health Technology Institute, </institution><institution>Kermanshah University of Medical Sciences, </institution></institution-wrap>Kermanshah, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.412112.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2012 5829</institution-id><institution>Department of Infection Disease, Faculty of Medicine, </institution><institution>Kermanshah University of Medical Sciences, </institution></institution-wrap>Kermanshah, Iran </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.412112.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2012 5829</institution-id><institution>Clinical Research Development Center, Imam Reza Hospital, </institution><institution>Kermanshah University of Medical Sciences, </institution></institution-wrap>Kermanshah, Iran </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.412112.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2012 5829</institution-id><institution>Research Center for Environmental Determinants of Health (RCEDH), Health Institute, </institution><institution>Kermanshah University of Medical Sciences, </institution></institution-wrap>Kermanshah, Iran </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.411950.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0611 9280</institution-id><institution>Department of Biostatistics, School of Public Health and Research Center for Health Sciences, </institution><institution>Hamadan University of Medical Sciences, </institution></institution-wrap>Hamadan, Iran </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>15</volume><elocation-id>24</elocation-id><history><date date-type="received"><day>21</day><month>12</month><year>2019</year></date><date date-type="accepted"><day>10</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Because alcohol use disorders (AUDs) in patients living with HIV/AIDS are associated with a reduction in therapeutic outcomes and increases the risk of morbidity/mortality, finding an appropriate pharmacotherapy treatment for this disorder is necessary.</p></sec><sec><title>Objectives</title><p id="Par2">This systematic review contains studies that examine the effects of pharmacological intervention (oral naltrexone (NTX) or injectable extended-release naltrexone (XR-NTX)) on the persons living with HIV and AUDs.</p></sec><sec><title>Methods</title><p id="Par3">A systematic literature search using three electronic databases including Pubmed Medline, Scopus and the Cochrane Library and Google Scholar was conducted and includes articles published from 1995 to 2019. Records were collected by searching relevant keywords and those that meet the inclusion/exclusion criteria are included.</p></sec><sec><title>Results</title><p id="Par4">Overall, in this systematic review, the results of 7 relevant studies including pilot and randomized controlled/clinical trials were summarized and reviewed. Among selected records 2 of these assessed the efficacy of NTX and 5 tested the XR-NTX effectiveness in treating AUDs among persons living with HIV (PLH). In summary, with some expectations, NTX and XR-NTX administration in persons living with HIV and AUDs led to reduced alcohol use, improved viral suppression, unchanged ART adherence and has no significant adverse events.</p></sec><sec><title>Conclusion</title><p id="Par5">The findings of this systematic review suggest the beneficial effects and safety of the NTX and XR-NTX for treating AUDs in PLH. Further studies are needed in the future to focus on the treatment of AUDs in people living with HIV.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alcohol use disorders (AUDs)</kwd><kwd>HIV</kwd><kwd>Naltrexone</kwd><kwd>Systematic review</kwd><kwd>Treatment</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012286</institution-id><institution>Deputy for Research and Technology, Kermanshah University of Medical Sciences</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par11">Alcohol use disorders (AUDs) are a costly, common and disabling health condition that is considered as one of the most serious public health problems [<xref ref-type="bibr" rid="CR1">1</xref>]. Alcohol use is highly prevalent among positive human immunodeficiency virus (HIV) individuals [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. Alcohol use in people living with HIV/AIDS seems to be 2&#x02013;4 times more prevalent than the general population [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>] and it has also been estimated that about 40&#x02013;50% of these patients had a history of heavy alcohol use [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. There are several harmful linkages between alcohol use and HIV. Heavy alcohol use has the ability for interfering with immune system functions [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>], increasing in the incidence of serious bacterial infections (especially tuberculosis) [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], liver damage and hepatotoxicity in the case of associated infection such as hepatitis C [<xref ref-type="bibr" rid="CR15">15</xref>], and make changes in the metabolism of antiretroviral drugs [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Moreover, heavy alcohol use is linked to the harmful behavior i.e. illicit drug use, smoking, and enhanced unsafe sexual activities. Besides, it has been reported that alcohol use is associated with an increase in the risk of chronic illnesses such as cardiovascular disease and cancer in people living with HIV [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Alcohol use among people living with HIV affects negatively on their adherence and engagement to the HIV treatment, treatment outcomes and mortality risk [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. There are various pharmacological/behavioral treatments for treating AUDs [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>]. Pharmacotherapy is recommended for AUD treatment [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], and FDA-approved medications for these disorders include acamprosate, disulfiram, and naltrexone [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Besides above-mentioned drugs, strong evidence found regarding the use of topiramate for AUD treatment in a meta-analysis study [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par12">Opioid antagonist, naltrexone (NTX) sold under the brand names Revia and Vivitrol among others, is an important pharmacological medication. Oral and injectable forms of naltrexone are commercially available [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. It is used for managing of AUDs and it is effective to reduce alcohol use and craving [<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]. This opioid receptor antagonist has a similar structure with morphine and has a high affinity for the &#x003bc;- and &#x003ba;-opioid receptor active sites [<xref ref-type="bibr" rid="CR38">38</xref>]. It is believed that NTX may lead to the antagonism of opioid pathways towards the nucleus accumbens, and thus reduces the amount of released dopamine [<xref ref-type="bibr" rid="CR39">39</xref>]. It has been demonstrated that NTX is effective in reducing the number of drinks and heavy alcohol use days and extends the rates of abstinence [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. The main goal of this research is to provide a systematic review of the current evidence regarding the application of naltrexone for the pharmacotherapy of AUDs in people living with HIV. The impact of oral naltrexone (NTX) and injectable extended-release form (XR-NTX) on the alcohol use and HIV related outcomes are discussed.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Searching strategy</title><p id="Par13">This study is designed according to the PRISMA statement [<xref ref-type="bibr" rid="CR43">43</xref>]. A systematic literature search was conducted on the online databases including Google Scholar, Pubmed Medline, Scopus, and the Cochrane Library until June 2019. The key search terms were: (naltrexone and HIV and alcohol) or (naltrexone and HIV and drinking) or (naltrexone and AIDS and alcohol) or (naltrexone and AIDS and drinking) or (Vivitrol and HIV and alcohol) or (Vivitrol and HIV and drinking) or (Vivitrol and AIDS and alcohol) or (Vivitrol and AIDS and alcohol) or (Revia and HIV and alcohol) or (Revia and HIV and drinking) or (Revia and AIDS and alcohol) or (Revia and AIDS and alcohol).</p></sec><sec id="Sec4"><title>Inclusion/exclusion criteria and study selection</title><p id="Par14">Only studies that investigate the efficacy of NTX or XR-NTX for treating AUDs in PLH to be included. Exclusion criteria in this study were as: 1) Review articles, animal studies and those studies that only reported the pharmacology effects, 2) Studies that reported NTX or XR-NTX for the treatment of opioid use disorders (OUDs) or AUDs in PLH but they did not report their results separately for the group with AUDs, 3) Studies that include NTX or XR-NTX in combination with other drugs, and 4) Studies in which patients, in addition to AIDS, are infected with other infectious diseases, such as hepatitis. After deleting duplicate records, remained studies were screened and relevant ones were selected based on suitability of their title and abstract.</p></sec><sec id="Sec5"><title>Data extraction and synthesize the results</title><p id="Par15">The seven included studies are pilot studies and randomized trials focusing on the treatment of AUDs in PLH. Reported outcomes including ART adherence, retention in treatment, drinking status, HIV-related biomarkers, and treatment safety. The summary of the included records is presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows the systematic searching strategy.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of the included records</p></caption><table frame="hsides" rules="groups"><thead><tr><th>No</th><th>Authors, year</th><th>Type of study</th><th>No of Participants</th><th>Intervention</th><th>Time of evaluation</th><th>Outcome</th></tr></thead><tbody><tr><td>1</td><td>Cook et al. 2017 [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td>Randomized clinical trial</td><td>17</td><td>Oral Naltrexone (50&#x02009;mg) for 4&#x02009;month</td><td>2, 4 and 7&#x02009;months</td><td>82% of participants completed the 7-month assessment. Alcohol use was reduced substantially in both groups.</td></tr><tr><td>2</td><td>Edelman et al. 2019 [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td>Randomized controlled trial</td><td>51</td><td>XR-NTX*, 380&#x02009;mg (4&#x02009;mL) injection for 24&#x02009;weeks</td><td>12, 24,32 and 56&#x02009;months</td><td>The XR-NTX had no effect on ART adherence and HIV markers. XR-NTX was associated with fewer heavy drinking days.</td></tr><tr><td>3</td><td>Korthuis et al. 2017b [<xref ref-type="bibr" rid="CR46">46</xref>]</td><td>Pilot study</td><td>29</td><td>XR-NTX injection for 8&#x02009;month</td><td>16&#x02009;weeks</td><td>Mean days of drinking to intoxication in the past 30&#x02009;days was decreased. HIV viral suppression was improved</td></tr><tr><td>4</td><td>Korthuis et al. 2017a [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td>Pilot/ Feasibility Randomized Trial</td><td>27</td><td>XR-NTX 380&#x02009;mg for 16&#x02009;months</td><td>16&#x02009;weeks</td><td>Mean heavy drinking days was decreased. HIV suppression was improved.</td></tr><tr><td>5</td><td>Springer et al. 2017</td><td>Randomized, double-blind, placebo-controlled trial</td><td>100</td><td>XR-NTX for 6&#x02009;month</td><td>6&#x02009;month</td><td>There was no significant differences between groups for drinking outcomes.</td></tr><tr><td>6</td><td>Springer et al. 2018 [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td>Double blind randomized placebo-controlled trial</td><td>100</td><td>XR-NTX for 6&#x02009;month</td><td>6&#x02009;month</td><td>The XR-NTX has improved or maintain the viral suppression (VS).</td></tr><tr><td>7</td><td>Hu et al. 2013 [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td>Double-blind, randomized controlled trial</td><td>19</td><td>Oral Naltrexone (50&#x02009;mg) for 4&#x02009;month</td><td>2, 4 and 7&#x02009;months</td><td>Average daily alcohol consumption was reduced.</td></tr></tbody></table></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>Searching strategy flow chart</p></caption><graphic xlink:href="13011_2020_266_Fig1_HTML" id="MO1"/></fig></p></sec></sec><sec id="Sec6"><title>Results</title><p id="Par16">As shown in Table <xref rid="Tab1" ref-type="table">1</xref>, two of these studies have used oral naltrexone (NTX) [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR49">49</xref>] and the 5 other used extended-release injectable form (XR-NTX) [<xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. The difference between reported outcomes and a small number of studies has made it difficult to present results in a meta-analysis. However, to illustrate the effect of the drug in each study, the total effect size of each study for repeated measurements at different time intervals was calculated and reported using a fixed effect model [<xref ref-type="bibr" rid="CR51">51</xref>].</p><sec id="Sec7"><title>Evaluated outcomes</title><sec id="Sec8"><title>Treatment retention</title><p id="Par17">Of the 51 participants who enrolled in the study by Edelman et al., 2019, only 23 participants remained in the study for up to 24&#x02009;weeks [<xref ref-type="bibr" rid="CR45">45</xref>]. 82% of Cook et al., 2017 study participants completed the course of treatment [<xref ref-type="bibr" rid="CR44">44</xref>]. Among 51 people with HIV/AUD enrolled in the study by Korthuis. et al., 2017, 83% of XR-NTX and 50% of treatment as usual (TAU) pharmacotherapy groups were retained on the treatment within 16&#x02009;weeks [<xref ref-type="bibr" rid="CR47">47</xref>]. Springer et al., 2018 studied the effects of XR-NTX on 100 (2:1 randomization) incarcerated individuals with HIV/AUD and reported no significant difference between treatment retention for both XR-NTX and placebo groups after 6&#x02009;months [<xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="Sec9"><title>Drinking outcomes</title><p id="Par18">Cook et al., 2017 conducted a study from 2010 to 2012 on the 17 women who have HIV with AUDs. They received naltrexone (daily 50&#x02009;mg orally) or placebo randomly to reduce drinking [<xref ref-type="bibr" rid="CR44">44</xref>]. Participants were divided to NTX (<italic>n</italic>&#x02009;=&#x02009;10) and placebo (<italic>n</italic>&#x02009;=&#x02009;7) groups. In both groups, during participants follow-up, the drinking reductions were observed in terms of decreased mean alcohol consumption per week (39.2 vs. 12.8 drinks/week at month 4 (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) and 9.4 drinks/week at month 7, (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05)) and increase in the number of abstinent days. Although these changes were significant for each group alone, there was no significant difference between the two treatment groups. Hu et al., 2013 investigated the effectiveness of using NTX in reducing heavy alcohol use on 19 women infected with HIV from 2010 to 2012 [<xref ref-type="bibr" rid="CR49">49</xref>]. They were randomized 2:1 and received 50&#x02009;mg NTX orally or placebo for 7-months. Among NTX group an average daily alcohol drinking significantly reduced from 7.13 at baseline to 0.46 standard drinking units at the end of 7&#x02009;month treatment. Edelman et al., 2019 examined the effects of XR-NTX on the 51 participants with HIV/AUDs from 2011 to 2015. Participants divided into 2 (XR-NTX or placebo) groups and followed throughout the 24-week treatment. The XR-NTX group received 380&#x02009;mg in 4&#x02009;mL intramuscularly at four-week intervals [<xref ref-type="bibr" rid="CR45">45</xref>]. Edelman et al., 2019 observed that compared to the placebo group, the XR-NTX assigned group had fewer past 30-day heavy and abstinent drinking days (<italic>p</italic>&#x02009;=&#x02009;0.03). Moreover, for the XR-NTX group phosphatidylethanol (PEth, an alcohol biomarker) values decreased over time (p&#x02009;=&#x02009;0.03) [<xref ref-type="bibr" rid="CR45">45</xref>]. Korthuis et al., 2017 assessed the effects of XR-NTX for treating AUDs in PLH. Patients were assigned to XR-NTX (<italic>n</italic>&#x02009;=&#x02009;12) versus treatment as usual (TAU, <italic>n</italic>&#x02009;=&#x02009;11) and followed during 8&#x02009;months [<xref ref-type="bibr" rid="CR46">46</xref>]. The past 30-day mean drinking days to intoxication decreased from 13 to 6 and 18 to 7 for XR-NTX and TAU groups, respectively. In another study reported by Springer et al. 2017, 100 HIV positive released prisoners with AUD were randomized 2:1 to XR-NTX or placebo groups to receive injections of XR-NTX or placebo for 6-month. Overall, there was no statistically significant difference for the time to first heavy drinking day, average drinks per drinking day, mean percent of heavy drinking day and mean change in alcohol craving. Compared to the placebo group, younger in age participants (age 20&#x02013;29&#x02009;years) in the XR-NTX group had a more time to first heavy drinking day.</p></sec><sec id="Sec10"><title>ART adherence</title><p id="Par19">Edelman et al., 2019 did not observe the difference in the proportion of participants with &#x02265;95% or&#x02009;&#x02265;&#x02009;90% ART adherence between treatment arms (<italic>p</italic>&#x02009;=&#x02009;0.38) or treatment arms over time (<italic>p</italic>&#x02009;=&#x02009;0.97) [<xref ref-type="bibr" rid="CR45">45</xref>]. There were no statistically significant differences in the proportion of participants with &#x02265;95% ART adherence (&#x0201c;The pooled effect size for ART adherence was OR=1.43, 95%CI: 0.38 to 5.39&#x0201d;) during the study done by Cook et al., 2017 [<xref ref-type="bibr" rid="CR44">44</xref>].</p></sec><sec id="Sec11"><title>HIV viral load</title><p id="Par20">In the case of women who received 50&#x02009;mg daily NTX in the study by Cook et al. 2017, undetectable HIV viral load increased from baseline after 2, 4 and 7&#x02009;months in both the NTX and placebo groups but these increase was not significant (&#x0201c;The pooled effect size for HIV viral load was OR=2.32, 95%CI: 0.56 to 9.71&#x0201d;) [<xref ref-type="bibr" rid="CR44">44</xref>]. Effect of XR-NTX on undetectable viral load (&#x0003c;&#x02009;50 copies/mL) was reported by Edelman et al. 2019, Springer et al., 2018 and Korthuis et al., 2017 [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Edelman et al. 2019 reported that compared to baseline, a significant increase in the proportion with an undetectable HIV viral load (defined as &#x0003c;&#x02009;50 copies/mL) was not detected (<italic>p</italic>&#x02009;=&#x02009;0.06) [<xref ref-type="bibr" rid="CR45">45</xref>]. For the placebo group involved in the Springer et al., 2018 study, there were no statistically-significant improve at each level of viral suppression from baseline to 6-month treatment. For the placebo group, the value of viral suppression (VS) at all three-level (&#x0003c;&#x02009;50, &#x0003c;&#x02009;200, and&#x02009;&#x0003c;&#x02009;400 copies/mL), didn&#x02019;t improve from baseline of 42, 64 and 66.7% to 30.3% (<italic>P</italic>&#x02009;=&#x02009;0.292), 42.4% (<italic>P</italic>&#x02009;=&#x02009;0.070) and 42.4% (<italic>P</italic>&#x02009;=&#x02009;0.030) after 6&#x02009;month treatment, respectively. VS for the XR-NTX group at two levels (&#x0003c;&#x02009;50, and&#x02009;&#x0003c;&#x02009;200 copies/mL) increased from baseline of 31, 48 to 56.7% (<italic>P</italic>&#x02009;=&#x02009;0.001) and 64.2% (<italic>P</italic>&#x02009;=&#x02009;0.024) after 6&#x02009;month, respectively. From baseline to 6&#x02009;months, the value of VS &#x0003c;&#x02009;400 copies/mL was maintained (63.6 to 53.7%, <italic>P</italic>&#x02009;=&#x02009;0.260). Also at 6&#x02009;months, XR-NTX receiving participants were more likely to have viral suppression for both &#x0003c;&#x02009;200 copies/mL and&#x02009;&#x0003c;&#x02009;50 copies/mL levels than placebo while there was no significant difference for viral suppression &#x0003c;&#x02009;400 copies/mL between two groups. Based on Korthuis et al., 2017 HIV viral suppression (HIV RNA pcr&#x02009;&#x0003c;&#x02009;200 copies/mL) changed from 92 to 82% for patients assigned to XR-NTX and no change was detected for TAU at 16&#x02009;weeks [<xref ref-type="bibr" rid="CR46">46</xref>].</p></sec><sec id="Sec12"><title>CD4 cell count</title><p id="Par21">For both NTX and placebo groups in the study by Cook et al., 2017, after 4 and 7&#x02009;month treatment, the CD4 counts improved than baseline and due to small amounts of numbers, it isn&#x02019;t possible to make meaningful conclusions (&#x0201c;The pooled effect size for CD4 counts was standard mean difference (SMD)=0.13, 95% CI: -0.48 to 0.73&#x0201d;) [<xref ref-type="bibr" rid="CR44">44</xref>]. Edelman et al., 2019 reported that for the XR-NTX group, the estimated mean CD4 was lower than the placebo group at baseline and this difference were not statistically-significant (<italic>p</italic>&#x02009;=&#x02009;0.75) [<xref ref-type="bibr" rid="CR45">45</xref>].</p></sec><sec id="Sec13"><title>VACS index score</title><p id="Par22">During the 24-week treatment period in the study of Edelman et al., 2019, there were no significant differences in the VACS index scores between the groups by condition (<italic>p</italic>&#x02009;=&#x02009;0.70), or over time (<italic>p</italic>&#x02009;=&#x02009;0.63) [<xref ref-type="bibr" rid="CR45">45</xref>].</p></sec></sec><sec id="Sec14"><title>Safety</title><p id="Par23">Cook et al., 2017 reported that however, the proportion of those reporting adverse event relating to drug consumption for NTX receiving participants are greater compared to placebo (70% vs. 28%), these differences were not significant statistically (<italic>p</italic>&#x02009;=&#x02009;0.15 by Fisher exact test) [<xref ref-type="bibr" rid="CR44">44</xref>]. According to Cook et al., 2017 the most common side effects for NTX users were: insomnia (30%), nervousness/anxiety (30%), and nausea (10%). Also, Springer et al., 2017 reported no statistical differences in adverse events between the XR-NTX or placebo groups [<xref ref-type="bibr" rid="CR50">50</xref>]. In another study by Edelman et al. 2019, 51% of participants experienced one or more adverse events with mild to moderate severity and 18% had a serious adverse event. The reported adverse events were different and include neurological, muscular, gastrointestinal, psychiatric, slips and falls, legal, family and social problems and other problems associated with using drug/alcohol [<xref ref-type="bibr" rid="CR45">45</xref>]. Among 51 patient participated in Korthuis et al., 2017 study, 40 of them experienced 29 adverse events but most of them (62%) were not associated with the study treatment [<xref ref-type="bibr" rid="CR47">47</xref>].</p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par24">HIV and AUDs are two of the prevalent epidemics and if they combined together leading to poor health outcomes and increased mortality/morbidity. Based on health treating complication related to alcohol use in PLH, it is crucial to explore efficacious pharmacological and behavioral interventions to treat AUDs. In this regard, this systematic review covering information from the literature contribute to the pharmacotherapy treating of AUDs in PLH. These studies are focused on whether AUD treatment can affect the important clinical and laboratory parameters affecting the evaluation and progression of AIDS. These studies use naltrexone (oral or injectable forms) to treat heavy alcohol use among PLH. Very few studies have been conducted to examine the outcomes of AUDs pharmacological treatments in PLH. Studies included in this work have examined the effects of NTX or XR-NTX on AUD treatment and reported different outcomes such as treatment retention (<italic>n</italic>&#x02009;=&#x02009;2), drinking status (<italic>n</italic>&#x02009;=&#x02009;5), antiretroviral therapy adherence (n&#x02009;=&#x02009;2), and biological HIV markers (n&#x02009;=&#x02009;5). Although these studies reported a change in alcohol intake during naltrexone use, the measurement criteria and timing are very different. So it is hard to summarize and compare their results. For example, studies have used different criteria for measuring and reporting drinking-related outcomes. These studies reported the mean alcohol drinking per week, the number of abstinent days per month, the past 30-day mean drinking days, time to first heavy drinking day, average drinks per drinking day, mean percent of heavy drinking day and mean change in alcohol craving in different intervals during the period of assessment. One study found an 83% of XR-NTX groups remained on treatment during 16&#x02009;weeks follow-up and in another study, a significant difference in remaining on treatment between XR-NTX and placebo groups did not find. Due to NTX administration, a reduced average daily alcohol drinking, mean weekly alcohol consumption and an increase in the number of the abstinent days was found by two studies. After treating with XR-NTX, fewer past 30-day mean and heavy drinking day was reported by 2 studies. In comparison to placebo, for both NTX and XR-NTX groups no statistically-significant differences for the proportion with &#x02265;95% ART adherence were reported. Undetectable HIV viral load or viral suppression did not increase significantly after NTX consumption. A statistically-significant VS improvement in the XR-NTX than the placebo group was reported by three studies. The amount of mean CD4 count improved slightly from baseline after NTX administration and there was also the lower CD4 count for XR-NTX group compared to placebo. Three studies did not find any statistically-significant adverse events for NTX and XR-NTX. Despite the importance of managing alcohol use disorders in PLH, only a limited number of studies have focused on this issue. The variety of responses considered for evaluating drug treatment outcomes, the low number of study participants, and the selection of the study population from specific groups such as prisons or newly released individuals are among problems associated with the limited studies conducted in this area.</p></sec><sec id="Sec16"><title>Conclusion</title><p id="Par25">This review study was designed to evaluate the effect of naltrexone on the outcomes of drinking and AIDS treatment in patients with these two conditions simultaneously. Results showed that administration of injectable/oral naltrexone in people living with HIV/AUDs reduces alcohol consumption and improves viral suppression without significant side effects. Thus naltrexone can be used to treat alcohol-related disorders in this group of patients. However, due to the small number of studies conducted in this field and the problems associated with alcohol consumption in AIDS patients, it seems that more prospective prolonged controlled trial studies are needed to address the impact of NTX and XR-NTX in people living with HIV/AUDs.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AUDs</term><def><p id="Par6">Alcohol use disorders</p></def></def-item><def-item><term>XR-NTX</term><def><p id="Par7">Extended-release naltrexone</p></def></def-item><def-item><term>NTX</term><def><p id="Par8">Oral naltrexone</p></def></def-item><def-item><term>OUDs</term><def><p id="Par9">Opioid use disorders</p></def></def-item><def-item><term>VS</term><def><p id="Par10">Viral suppression</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors are acknowledged to the Kermanshah University of Medical Sciences for supporting the work.</p><sec id="FPar1"><title>Declaration</title><p id="Par26">None.</p></sec></ack><notes notes-type="author-contribution"><title>Author&#x02019;s contributions</title><p>Study design: N. Farhadian, M. Farhadian, Shahlaei, Farnia; data interpretation: M. Farhadian, Rezaeian, Zamanian, Farnia; first draft: N. Farhadian; Moradi; editing: Shahlaei, Moradi; searching process: N. Farhadian, M. Farhadian; all authors contributed to final review/approve of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Kermanshah University of Medical Sciences.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par27">Not applicable.</p></notes><notes><title>Consent for publication</title><p id="Par28">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par29">None.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>CM</given-names></name><name><surname>Mendoza-Sassi</surname><given-names>RA</given-names></name><name><surname>da Mota</surname><given-names>LD</given-names></name><name><surname>Nader</surname><given-names>MM</given-names></name><name><surname>de Martinez</surname><given-names>AMB</given-names></name></person-group><article-title>Alcohol use disorders among people living with HIV/AIDS in southern Brazil: prevalence, risk factors and biological markers outcomes</article-title><source>BMC Infect Dis</source><year>2017</year><volume>17</volume><fpage>263</fpage><pub-id pub-id-type="doi">10.1186/s12879-017-2374-0</pub-id><?supplied-pmid 28399823?><pub-id pub-id-type="pmid">28399823</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>GL</given-names></name><name><surname>Wasley</surname><given-names>A</given-names></name><name><surname>Simard</surname><given-names>EP</given-names></name><name><surname>McQuillan</surname><given-names>GM</given-names></name><name><surname>Kuhnert</surname><given-names>WL</given-names></name><name><surname>Alter</surname><given-names>MJ</given-names></name></person-group><article-title>The prevalence of hepatitis C virus infection in the United States, 1999 through 2002</article-title><source>Ann Intern Med</source><year>2006</year><volume>144</volume><fpage>705</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-144-10-200605160-00004</pub-id><?supplied-pmid 16702586?><pub-id pub-id-type="pmid">16702586</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galvan</surname><given-names>FH</given-names></name><name><surname>Bing</surname><given-names>EG</given-names></name><name><surname>Fleishman</surname><given-names>JA</given-names></name><name><surname>London</surname><given-names>AS</given-names></name><name><surname>Caetano</surname><given-names>R</given-names></name><name><surname>Burnam</surname><given-names>MA</given-names></name><name><surname>Longshore</surname><given-names>D</given-names></name><name><surname>Morton</surname><given-names>SC</given-names></name><name><surname>Orlando</surname><given-names>M</given-names></name><name><surname>Shapiro</surname><given-names>M</given-names></name></person-group><article-title>The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV cost and services utilization study</article-title><source>J Stud Alcohol</source><year>2002</year><volume>63</volume><fpage>179</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.15288/jsa.2002.63.179</pub-id><?supplied-pmid 12033694?><pub-id pub-id-type="pmid">12033694</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>AL</given-names></name><name><surname>Denniston</surname><given-names>MM</given-names></name><name><surname>Klevens</surname><given-names>RM</given-names></name><name><surname>McKnight-Eily</surname><given-names>LR</given-names></name><name><surname>Jiles</surname><given-names>RB</given-names></name></person-group><article-title>Association of hepatitis C virus with alcohol use among US adults: NHANES 2003&#x02013;2010</article-title><source>Am J Prev Med</source><year>2016</year><volume>51</volume><fpage>206</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2016.02.033</pub-id><?supplied-pmid 27178884?><pub-id pub-id-type="pmid">27178884</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>EC</given-names></name><name><surname>Joo</surname><given-names>YS</given-names></name><name><surname>Lipira</surname><given-names>L</given-names></name><name><surname>Glass</surname><given-names>JE</given-names></name></person-group><article-title>Psychosocial stressors and alcohol use, severity, and treatment receipt across HIV status in a nationally representative sample of US residents</article-title><source>Subst Abus</source><year>2017</year><volume>38</volume><fpage>269</fpage><pub-id pub-id-type="doi">10.1080/08897077.2016.1268238</pub-id><?supplied-pmid 27925867?><pub-id pub-id-type="pmid">27925867</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petry</surname><given-names>NM</given-names></name></person-group><article-title>Alcohol use in HIV patients: what we don't know may hurt us</article-title><source>Int J STD AIDS</source><year>1999</year><volume>10</volume><fpage>561</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1258/0956462991914654</pub-id><?supplied-pmid 10492422?><pub-id pub-id-type="pmid">10492422</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vagenas</surname><given-names>P</given-names></name><name><surname>Azar</surname><given-names>MM</given-names></name><name><surname>Copenhaver</surname><given-names>MM</given-names></name><name><surname>Springer</surname><given-names>SA</given-names></name><name><surname>Molina</surname><given-names>PE</given-names></name><name><surname>Altice</surname><given-names>FL</given-names></name></person-group><article-title>The impact of alcohol use and related disorders on the HIV continuum of care: a systematic review</article-title><source>CURR HIV-AIDS REP</source><year>2015</year><volume>12</volume><fpage>421</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1007/s11904-015-0285-5</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefevre</surname><given-names>F</given-names></name><name><surname>O&#x02019;Leary</surname><given-names>B</given-names></name><name><surname>Moran</surname><given-names>M</given-names></name><name><surname>Mossar</surname><given-names>M</given-names></name><name><surname>Yarnold</surname><given-names>PR</given-names></name><name><surname>Martin</surname><given-names>GJ</given-names></name><name><surname>Glassroth</surname><given-names>J</given-names></name></person-group><article-title>Alcohol consumption among HIV-infected patients</article-title><source>J Gen Intern Med</source><year>1995</year><volume>10</volume><fpage>458</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1007/BF02599920</pub-id><?supplied-pmid 7472704?><pub-id pub-id-type="pmid">7472704</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samet</surname><given-names>JH</given-names></name><name><surname>Phillips</surname><given-names>SJ</given-names></name><name><surname>Horton</surname><given-names>NJ</given-names></name><name><surname>Traphagen</surname><given-names>ET</given-names></name><name><surname>Freedberg</surname><given-names>KA</given-names></name></person-group><article-title>Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire</article-title><source>AIDS RES HUM RETROV</source><year>2004</year><volume>20</volume><fpage>151</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1089/088922204773004860</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagasra</surname><given-names>O</given-names></name><name><surname>Bachman</surname><given-names>SE</given-names></name><name><surname>Jew</surname><given-names>L</given-names></name><name><surname>Tawadros</surname><given-names>R</given-names></name><name><surname>Cater</surname><given-names>J</given-names></name><name><surname>Boden</surname><given-names>G</given-names></name><name><surname>Ryan</surname><given-names>I</given-names></name><name><surname>Pomerantz</surname><given-names>RJ</given-names></name></person-group><article-title>Increased human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells induced by ethanol: potential immunopathogenic mechanisms</article-title><source>J Infect Dis</source><year>1996</year><volume>173</volume><fpage>550</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1093/infdis/173.3.550</pub-id><?supplied-pmid 8627016?><pub-id pub-id-type="pmid">8627016</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romeo</surname><given-names>J</given-names></name><name><surname>W&#x000e4;rnberg</surname><given-names>J</given-names></name><name><surname>Nova</surname><given-names>E</given-names></name><name><surname>D&#x000ed;az</surname><given-names>LE</given-names></name><name><surname>G&#x000f3;mez-Martinez</surname><given-names>S</given-names></name><name><surname>Marcos</surname><given-names>A</given-names></name></person-group><article-title>Moderate alcohol consumption and the immune system: a review</article-title><source>Br J Nutr</source><year>2007</year><volume>98</volume><fpage>S111</fpage><lpage>S115</lpage><pub-id pub-id-type="doi">10.1017/S0007114507838049</pub-id><?supplied-pmid 17922947?><pub-id pub-id-type="pmid">17922947</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname><given-names>G</given-names></name></person-group><article-title>Consequences of alcohol consumption on host defence</article-title><source>Alcohol Alcohol</source><year>1999</year><volume>34</volume><fpage>830</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1093/alcalc/34.6.830</pub-id><?supplied-pmid 10659718?><pub-id pub-id-type="pmid">10659718</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Amoakwa, K., Martinson, N. A., Moulton, L. H., Barnes, G. L., Msandiwa, R., Chaisson, R. E.: Risk factors for developing active tuberculosis after the treatment of latent tuberculosis in adults infected with human immunodeficiency virus. In Open forum infectious diseases (Vol. 2, pp. ofu120): Oxford University Press (2015).</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manno</surname><given-names>D</given-names></name><name><surname>Puoti</surname><given-names>M</given-names></name><name><surname>Signorini</surname><given-names>L</given-names></name><name><surname>Lapadula</surname><given-names>G</given-names></name><name><surname>Cadeo</surname><given-names>B</given-names></name><name><surname>Soavi</surname><given-names>L</given-names></name><name><surname>Paraninfo</surname><given-names>G</given-names></name><name><surname>Allegri</surname><given-names>R</given-names></name><name><surname>Cristini</surname><given-names>G</given-names></name><name><surname>Viale</surname><given-names>P</given-names></name></person-group><article-title>Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis</article-title><source>Infection</source><year>2009</year><volume>37</volume><fpage>334</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1007/s15010-009-8140-5</pub-id><?supplied-pmid 19629382?><pub-id pub-id-type="pmid">19629382</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benhamou</surname><given-names>Y</given-names></name><name><surname>Bochet</surname><given-names>M</given-names></name><name><surname>Di Martino</surname><given-names>V</given-names></name><name><surname>Charlotte</surname><given-names>F</given-names></name><name><surname>Azria</surname><given-names>F</given-names></name><name><surname>Coutellier</surname><given-names>A</given-names></name><name><surname>Vidaud</surname><given-names>M</given-names></name><name><surname>Bricaire</surname><given-names>F</given-names></name><name><surname>Opolon</surname><given-names>P</given-names></name><name><surname>Katlama</surname><given-names>C</given-names></name></person-group><article-title>Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients</article-title><source>Hepatology</source><year>1999</year><volume>30</volume><fpage>1054</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1002/hep.510300409</pub-id><?supplied-pmid 10498659?><pub-id pub-id-type="pmid">10498659</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Differential effects of ethanol on spectral binding and inhibition of cytochrome P450 3A4 with eight protease inhibitors antiretroviral drugs</article-title><source>Alcohol Clin Exp Res</source><year>2011</year><volume>35</volume><fpage>2121</fpage><lpage>2127</lpage><pub-id pub-id-type="doi">10.1111/j.1530-0277.2011.01575.x</pub-id><?supplied-pmid 21682753?><pub-id pub-id-type="pmid">21682753</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDowell</surname><given-names>JA</given-names></name><name><surname>Chittick</surname><given-names>GE</given-names></name><name><surname>Stevens</surname><given-names>CP</given-names></name><name><surname>Edwards</surname><given-names>KD</given-names></name><name><surname>Stein</surname><given-names>DS</given-names></name></person-group><article-title>Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults</article-title><source>Antimicrob Agents Chemother</source><year>2000</year><volume>44</volume><fpage>1686</fpage><lpage>1690</lpage><pub-id pub-id-type="doi">10.1128/AAC.44.6.1686-1690.2000</pub-id><?supplied-pmid 10817729?><pub-id pub-id-type="pmid">10817729</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Giovannucci</surname><given-names>EL</given-names></name></person-group><article-title>Light to moderate intake of alcohol, drinking patterns, and risk of cancer: results from two prospective US cohort studies</article-title><source>Bmj</source><year>2015</year><volume>351</volume><fpage>h4238</fpage><pub-id pub-id-type="doi">10.1136/bmj.h4238</pub-id><?supplied-pmid 26286216?><pub-id pub-id-type="pmid">26286216</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Bataller</surname><given-names>R</given-names></name></person-group><article-title>Alcoholic liver disease: pathogenesis and new therapeutic targets</article-title><source>Gastroenterology</source><year>2011</year><volume>141</volume><fpage>1572</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2011.09.002</pub-id><?supplied-pmid 21920463?><pub-id pub-id-type="pmid">21920463</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelso</surname><given-names>NE</given-names></name><name><surname>Sheps</surname><given-names>DS</given-names></name><name><surname>Cook</surname><given-names>RL</given-names></name></person-group><article-title>The association between alcohol use and cardiovascular disease among people living with HIV: a systematic review</article-title><source>Am J Drug Alcohol Abuse</source><year>2015</year><volume>41</volume><fpage>479</fpage><lpage>488</lpage><?supplied-pmid 26286352?><pub-id pub-id-type="pmid">26286352</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>Lesley S.</given-names></name><name><surname>Hern&#x000e1;ndez-Ram&#x000ed;rez</surname><given-names>Ra&#x000fa;l U.</given-names></name><name><surname>Silverberg</surname><given-names>Michael J.</given-names></name><name><surname>Crothers</surname><given-names>Kristina</given-names></name><name><surname>Dubrow</surname><given-names>Robert</given-names></name></person-group><article-title>Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS</article-title><source>AIDS</source><year>2016</year><volume>30</volume><issue>2</issue><fpage>273</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000922</pub-id><?supplied-pmid 26691548?><pub-id pub-id-type="pmid">26691548</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>CJ</given-names></name><name><surname>Ryom</surname><given-names>L</given-names></name><name><surname>Weber</surname><given-names>R</given-names></name><name><surname>Morlat</surname><given-names>P</given-names></name><name><surname>Pradier</surname><given-names>C</given-names></name><name><surname>Reiss</surname><given-names>P</given-names></name><name><surname>Kowalska</surname><given-names>JD</given-names></name><name><surname>De Wit</surname><given-names>S</given-names></name><name><surname>Law</surname><given-names>M</given-names></name><name><surname>el Sadr</surname><given-names>W</given-names></name></person-group><article-title>Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: a: D): a multicohort collaboration</article-title><source>Lancet</source><year>2014</year><volume>384</volume><issue>9939</issue><fpage>241</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)60604-8</pub-id><?supplied-pmid 25042234?><pub-id pub-id-type="pmid">25042234</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edelman</surname><given-names>EJ</given-names></name><name><surname>Williams</surname><given-names>EC</given-names></name><name><surname>Marshall</surname><given-names>BD</given-names></name></person-group><article-title>Addressing unhealthy alcohol use among people living with HIV: recent advances and research directions</article-title><source>Curr Opin Infect Dis</source><year>2018</year><volume>31</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/QCO.0000000000000422</pub-id><?supplied-pmid 29176446?><pub-id pub-id-type="pmid">29176446</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>EC</given-names></name><name><surname>Hahn</surname><given-names>JA</given-names></name><name><surname>Saitz</surname><given-names>R</given-names></name><name><surname>Bryant</surname><given-names>K</given-names></name><name><surname>Lira</surname><given-names>MC</given-names></name><name><surname>Samet</surname><given-names>JH</given-names></name></person-group><article-title>Alcohol use and human immunodeficiency virus (HIV) infection: current knowledge, implications, and future directions</article-title><source>Alcohol Clin Exp Res</source><year>2016</year><volume>40</volume><fpage>2056</fpage><lpage>2072</lpage><pub-id pub-id-type="doi">10.1111/acer.13204</pub-id><?supplied-pmid 27696523?><pub-id pub-id-type="pmid">27696523</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">William,s E.C., McGinnis, K.A., Edelman, E.J., Matson, T.E., Gordon, A.J., Marshall, B.D., Bryant, K.J., Rubinsky, A.D., Lapham, G.T., Satre, D.D.: Level of Alcohol Use Associated with HIV Care Continuum Targets in a National US Sample of Persons Living with HIV Receiving Healthcare. AIDS and Behavior 23 , 140&#x02013;151 (2019).</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anton</surname><given-names>RF</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>SS</given-names></name><name><surname>Ciraulo</surname><given-names>DA</given-names></name><name><surname>Cisler</surname><given-names>RA</given-names></name><name><surname>Couper</surname><given-names>D</given-names></name><name><surname>Donovan</surname><given-names>DM</given-names></name><name><surname>Gastfriend</surname><given-names>DR</given-names></name><name><surname>Hosking</surname><given-names>JD</given-names></name><name><surname>Johnson</surname><given-names>BA</given-names></name><name><surname>LoCastro</surname><given-names>JS</given-names></name></person-group><article-title>Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial</article-title><source>Jama</source><year>2006</year><volume>295</volume><fpage>2003</fpage><lpage>2017</lpage><pub-id pub-id-type="doi">10.1001/jama.295.17.2003</pub-id><?supplied-pmid 16670409?><pub-id pub-id-type="pmid">16670409</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>DA</given-names></name><name><surname>Grant</surname><given-names>BF</given-names></name><name><surname>Stinson</surname><given-names>FS</given-names></name><name><surname>Chou</surname><given-names>PS</given-names></name></person-group><article-title>Estimating the effect of help-seeking on achieving recovery from alcohol dependence</article-title><source>Addiction</source><year>2006</year><volume>101</volume><fpage>824</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1111/j.1360-0443.2006.01433.x</pub-id><?supplied-pmid 16696626?><pub-id pub-id-type="pmid">16696626</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>DE</given-names></name><name><surname>Amick</surname><given-names>HR</given-names></name><name><surname>Feltner</surname><given-names>C</given-names></name><name><surname>Bobashev</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>K</given-names></name><name><surname>Wines</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>MM</given-names></name><name><surname>Shanahan</surname><given-names>E</given-names></name><name><surname>Gass</surname><given-names>CE</given-names></name><name><surname>Rowe</surname><given-names>CJ</given-names></name></person-group><article-title>Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis</article-title><source>Jama</source><year>2014</year><volume>311</volume><fpage>1889</fpage><lpage>1900</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.3628</pub-id><?supplied-pmid 24825644?><pub-id pub-id-type="pmid">24825644</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lingford-Hughes</surname><given-names>AR</given-names></name><name><surname>Welch</surname><given-names>S</given-names></name><name><surname>Peters</surname><given-names>L</given-names></name><name><surname>Nutt</surname><given-names>D</given-names></name></person-group><article-title>BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP</article-title><source>J Psychopharmacol</source><year>2012</year><volume>26</volume><fpage>899</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1177/0269881112444324</pub-id><?supplied-pmid 22628390?><pub-id pub-id-type="pmid">22628390</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettinati</surname><given-names>HM</given-names></name><name><surname>Weiss</surname><given-names>RD</given-names></name><name><surname>Dundon</surname><given-names>W</given-names></name><name><surname>Miller</surname><given-names>WR</given-names></name><name><surname>Donovan</surname><given-names>D</given-names></name><name><surname>Ernst</surname><given-names>DB</given-names></name><name><surname>Rounsaville</surname><given-names>BJ</given-names></name></person-group><article-title>A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence</article-title><source>J Stud Alcohol Drugs Suppl</source><year>2005</year><volume>15</volume><fpage>170</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.15288/jsas.2005.s15.170</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisner</surname><given-names>C</given-names></name><name><surname>Matzger</surname><given-names>H</given-names></name><name><surname>Kaskutas</surname><given-names>LA</given-names></name></person-group><article-title>How important is treatment?</article-title><source>One-year outcomes of treated and untreated alcohol-dependent individuals Addiction</source><year>2003</year><volume>98</volume><fpage>901</fpage><lpage>911</lpage><?supplied-pmid 12814496?><pub-id pub-id-type="pmid">12814496</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Abuse NIoA, Alcoholism. Helping Patients who Drink Too Much: A Clinician's Guide: Updated 2005 Edition: US Department of Health and Human Services, National Institutes of Health &#x02026;, (2007).</mixed-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garbutt</surname><given-names>JC</given-names></name><name><surname>Kranzler</surname><given-names>HR</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>SS</given-names></name><name><surname>Gastfriend</surname><given-names>DR</given-names></name><name><surname>Pettinati</surname><given-names>HM</given-names></name><name><surname>Silverman</surname><given-names>BL</given-names></name><name><surname>Loewy</surname><given-names>JW</given-names></name><name><surname>Ehrich</surname><given-names>EW</given-names></name><collab>Group, V.S</collab></person-group><article-title>Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial</article-title><source>Jama</source><year>2005</year><volume>293</volume><fpage>1617</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1001/jama.293.13.1617</pub-id><?supplied-pmid 15811981?><pub-id pub-id-type="pmid">15811981</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helstrom</surname><given-names>AW</given-names></name><name><surname>Blow</surname><given-names>FC</given-names></name><name><surname>Slaymaker</surname><given-names>V</given-names></name><name><surname>Kranzler</surname><given-names>HR</given-names></name><name><surname>Leong</surname><given-names>S</given-names></name><name><surname>Oslin</surname><given-names>D</given-names></name></person-group><article-title>Reductions in alcohol craving following naltrexone treatment for heavy drinking</article-title><source>Alcohol Alcohol</source><year>2016</year><volume>51</volume><fpage>562</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1093/alcalc/agw038</pub-id><?supplied-pmid 27402770?><pub-id pub-id-type="pmid">27402770</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monti</surname><given-names>PM</given-names></name><name><surname>Rohsenow</surname><given-names>DJ</given-names></name><name><surname>Hutchison</surname><given-names>KE</given-names></name><name><surname>Swift</surname><given-names>RM</given-names></name><name><surname>Mueller</surname><given-names>TI</given-names></name><name><surname>Colby</surname><given-names>SM</given-names></name><name><surname>Brown</surname><given-names>RA</given-names></name><name><surname>Gulliver</surname><given-names>SB</given-names></name><name><surname>Gordon</surname><given-names>A</given-names></name><name><surname>Abrams</surname><given-names>DB</given-names></name></person-group><article-title>Naltrexone's effect on cue-elicited craving among alcoholics in treatment</article-title><source>Alcohol Clin Exp Res</source><year>1999</year><volume>23</volume><fpage>1386</fpage><lpage>1394</lpage><?supplied-pmid 10470982?><pub-id pub-id-type="pmid">10470982</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Ray LA, Chin PF, Miotto K. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS &#x00026; Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS &#x00026; Neurological Disorders). 2010;9(13&#x02013;22).</mixed-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volpicelli</surname><given-names>JR</given-names></name><name><surname>Alterman</surname><given-names>AI</given-names></name><name><surname>Hayashida</surname><given-names>M</given-names></name><name><surname>O'Brien</surname><given-names>CP</given-names></name></person-group><article-title>Naltrexone in the treatment of alcohol dependence</article-title><source>Arch Gen Psychiatry</source><year>1992</year><volume>49</volume><issue>11</issue><fpage>876</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1992.01820110040006</pub-id><?supplied-pmid 1345133?><pub-id pub-id-type="pmid">1345133</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Metcalf MD, Coop A. Kappa opioid antagonists: past successes and future prospects. In Drug Addiction: Springer 395&#x02013;431 (2008).</mixed-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goonoo</surname><given-names>N</given-names></name><name><surname>Bhaw-Luximon</surname><given-names>A</given-names></name><name><surname>Ujoodha</surname><given-names>R</given-names></name><name><surname>Jhugroo</surname><given-names>A</given-names></name><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>Jhurry</surname><given-names>D</given-names></name></person-group><article-title>Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems</article-title><source>J Control Release</source><year>2014</year><volume>183</volume><fpage>154</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2014.03.046</pub-id><?supplied-pmid 24704710?><pub-id pub-id-type="pmid">24704710</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ciraulo</surname><given-names>DA</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><name><surname>Silverman</surname><given-names>BL</given-names></name><name><surname>Gastfriend</surname><given-names>DR</given-names></name></person-group><source>Pettinati</source><year>2008</year><publisher-loc>Early treatment response in alcohol dependence with extended-release naltrexone. J Clin Psychiatry</publisher-loc><publisher-name>H.M</publisher-name></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cr&#x000e8;vecoeur-MacPhail</surname><given-names>D</given-names></name><name><surname>Cousins</surname><given-names>SJ</given-names></name><name><surname>Denering</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Rawson</surname><given-names>RA</given-names></name></person-group><article-title>Effectiveness of extended release naltrexone to reduce alcohol cravings and use behaviors during treatment and at follow-up</article-title><source>J Subst Abus Treat</source><year>2018</year><volume>85</volume><fpage>105</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2017.11.004</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapham</surname><given-names>S</given-names></name><name><surname>Forman</surname><given-names>R</given-names></name><name><surname>Alexander</surname><given-names>M</given-names></name><name><surname>Illeperuma</surname><given-names>A</given-names></name><name><surname>Bohn</surname><given-names>MJ</given-names></name></person-group><article-title>The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients</article-title><source>J Subst Abus Treat</source><year>2009</year><volume>36</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2008.07.001</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberati</surname><given-names>A.</given-names></name><name><surname>Altman</surname><given-names>D. G</given-names></name><name><surname>Tetzlaff</surname><given-names>J.</given-names></name><name><surname>Mulrow</surname><given-names>C.</given-names></name><name><surname>Gotzsche</surname><given-names>P. C</given-names></name><name><surname>Ioannidis</surname><given-names>J. P A</given-names></name><name><surname>Clarke</surname><given-names>M.</given-names></name><name><surname>Devereaux</surname><given-names>P J</given-names></name><name><surname>Kleijnen</surname><given-names>J.</given-names></name><name><surname>Moher</surname><given-names>D.</given-names></name></person-group><article-title>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration</article-title><source>BMJ</source><year>2009</year><volume>339</volume><issue>jul21 1</issue><fpage>b2700</fpage><lpage>b2700</lpage><pub-id pub-id-type="doi">10.1136/bmj.b2700</pub-id><?supplied-pmid 19622552?><pub-id pub-id-type="pmid">19622552</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>RL</given-names></name><name><surname>Weber</surname><given-names>KM</given-names></name><name><surname>Mai</surname><given-names>D</given-names></name><name><surname>Thoma</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Brumback</surname><given-names>B</given-names></name><name><surname>Karki</surname><given-names>M</given-names></name><name><surname>Bryant</surname><given-names>K</given-names></name><name><surname>Rathore</surname><given-names>M</given-names></name><name><surname>Young</surname><given-names>M</given-names></name></person-group><article-title>Acceptability and feasibility of a randomized clinical trial of oral naltrexone vs. placebo for women living with HIV infection: study design challenges and pilot study results</article-title><source>Contemp Clin Trials</source><year>2017</year><volume>60</volume><fpage>72</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.cct.2017.06.012</pub-id><?supplied-pmid 28642209?><pub-id pub-id-type="pmid">28642209</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edelman</surname><given-names>EJ</given-names></name><name><surname>Moore</surname><given-names>BA</given-names></name><name><surname>Holt</surname><given-names>SR</given-names></name><name><surname>Hansen</surname><given-names>N</given-names></name><name><surname>Kyriakides</surname><given-names>TC</given-names></name><name><surname>Virata</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>ST</given-names></name><name><surname>Justice</surname><given-names>AC</given-names></name><name><surname>Bryant</surname><given-names>KJ</given-names></name><name><surname>Fiellin</surname><given-names>DA</given-names></name></person-group><article-title>Efficacy of extended-release naltrexone on HIV-related and drinking outcomes among HIV-positive patients: a randomized-controlled trial</article-title><source>AIDS Behav</source><year>2019</year><volume>23</volume><fpage>211</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1007/s10461-018-2241-z</pub-id><?supplied-pmid 30073637?><pub-id pub-id-type="pmid">30073637</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korthuis</surname><given-names>T</given-names></name><name><surname>Lum</surname><given-names>PJ</given-names></name><name><surname>Vergara-Rodriguez</surname><given-names>P</given-names></name><name><surname>Ahamad</surname><given-names>K</given-names></name><name><surname>Wood</surname><given-names>E</given-names></name><name><surname>Lindblad</surname><given-names>R</given-names></name><name><surname>Mandler</surname><given-names>R</given-names></name><name><surname>Sorensen</surname><given-names>J</given-names></name><name><surname>Ha</surname><given-names>D</given-names></name><name><surname>Oden</surname><given-names>N</given-names></name></person-group><article-title>Extended-release naltrexone feasibility in HIV clinics: a pilot study</article-title><source>Drug Alcohol Depend</source><year>2017</year><volume>100</volume><fpage>e108</fpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2016.08.303</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korthuis</surname><given-names>PT</given-names></name><name><surname>Lum</surname><given-names>PJ</given-names></name><name><surname>Vergara-Rodriguez</surname><given-names>P</given-names></name><name><surname>Ahamad</surname><given-names>K</given-names></name><name><surname>Wood</surname><given-names>E</given-names></name><name><surname>Kunkel</surname><given-names>LE</given-names></name><name><surname>Oden</surname><given-names>NL</given-names></name><name><surname>Lindblad</surname><given-names>R</given-names></name><name><surname>Sorensen</surname><given-names>JL</given-names></name><name><surname>Arenas</surname><given-names>V</given-names></name></person-group><article-title>Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial</article-title><source>Addiction</source><year>2017</year><volume>112</volume><fpage>1036</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1111/add.13753</pub-id><?supplied-pmid 28061017?><pub-id pub-id-type="pmid">28061017</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Springer</surname><given-names>SA</given-names></name><name><surname>Di Paola</surname><given-names>A</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Azar</surname><given-names>MM</given-names></name><name><surname>Altice</surname><given-names>FL</given-names></name></person-group><article-title>Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV and alcohol use disorders transitioning to the community: results from a double-blind, placebo-controlled trial</article-title><source>JAIDS Journal of Acquired Immune Deficiency Syndromes</source><year>2018</year><volume>79</volume><fpage>92</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000001759</pub-id><?supplied-pmid 29781884?><pub-id pub-id-type="pmid">29781884</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Weber</surname><given-names>K</given-names></name><name><surname>Karki</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Young</surname><given-names>M</given-names></name><name><surname>Thoma</surname><given-names>K</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Rathore</surname><given-names>M</given-names></name><name><surname>Mai</surname><given-names>D</given-names></name><name><surname>Cook</surname><given-names>R</given-names></name></person-group><article-title>A pilot study of pharmacotherapy (naltrexone) for hazardous drinking among women infected with HIV</article-title><source>Value Health</source><year>2013</year><volume>16</volume><fpage>A70</fpage><pub-id pub-id-type="doi">10.1016/j.jval.2013.03.312</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Springer</surname><given-names>SA</given-names></name><name><surname>Di Paola</surname><given-names>A</given-names></name><name><surname>Azar</surname><given-names>MM</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Krishnan</surname><given-names>A</given-names></name><name><surname>Altice</surname><given-names>FL</given-names></name></person-group><article-title>Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community</article-title><source>Drug Alcohol Depend</source><year>2017</year><volume>174</volume><fpage>158</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2017.01.026</pub-id><?supplied-pmid 28334661?><pub-id pub-id-type="pmid">28334661</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouaffak</surname><given-names>F</given-names></name><name><surname>Leite</surname><given-names>C</given-names></name><name><surname>Hamzaoui</surname><given-names>S</given-names></name><name><surname>Benyamina</surname><given-names>A</given-names></name><name><surname>Laqueille</surname><given-names>X</given-names></name><name><surname>Kebir</surname><given-names>O</given-names></name></person-group><article-title>Naltrexone in the treatment of broadly defined behavioral addictions: a review and meta-analysis of randomized controlled trials</article-title><source>Eur Addict Res</source><year>2017</year><volume>23</volume><fpage>204</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1159/000480539</pub-id><?supplied-pmid 28877518?><pub-id pub-id-type="pmid">28877518</pub-id></element-citation></ref></ref-list></back></article>